HER2 gene amplification in primary mucinous ovarian cancer: A potential therapeutic target

Histopathology

Volumn 57, Issue 5, 2010, Pages 763-764

  Han, Chih Ping ^a,b   Hsu, Jeng Dong ^a,b   Yao, Chung Chin ^b,c   Lee, Ming Yung ^d   Ruan, Alexandra ^e   Tyan, Yeu Sheng ^c   Yang, Shun Fa ^b   Chiang, Hung ^f  

^a Department of Obstetrics and Gynecology ^*  (Taiwan)

^b Institute of Medicine   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d PROVIDENCE UNIVERSITY   (Taiwan)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Taipei Institute of Pathology   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CANCER THERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; LETTER; OVARY CANCER; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; FEMALE; GENE AMPLIFICATION; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2;

EID: 78449292896     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03689.x     Document Type: Letter

References (6)

1. Liao CL, Lee MY, Tyan YS et al. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J. Transl. Med. 2009; 7; 37.
2. Wolff AC, Hammond ME, Schwartz JN et al., American Society of Clinical Oncology; College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
3. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003; 21; 283-290.
4. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am. J. Surg. Pathol. 2003; 27; 985-993.
5. Seidman JD, Horkayne-Szakaly I, Haiba M et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004; 23; 41-44.
6. Köbel M, Kalloger SE, Huntsman DG et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 2010; 29; 203-211.